Victory Capital Management
EWTX icon

Victory Capital Management’s Edgewise Therapeutics EWTX Stock Holding History

Victory Capital Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24.9M Buy
789,043
+42,481
+6% +$1.23M 0.02% 787
2025
Q4 		$18.5M Buy
746,562
+247,916
+50% +$4.98M 0.01% 881
2025
Q3 		$8.09M Buy
498,646
+55,809
+13% +$792K ﹤0.01% 1182
2025
Q2 		$5.81M Buy
+442,837
New +$6.39M ﹤0.01% 1265
2025
Q1 		– Sell
-21,568
Closed -$576K – 2494
2024
Q4 		$576K Buy
+21,568
New +$687K ﹤0.01% 1992

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Victory Capital Management's EWTX Position: Q1 2026 in Review

Victory Capital Management increased its Edgewise Therapeutics (EWTX) stake by 5.7% in Q1 2026, buying an estimated $1.23M and bringing the position to 789,043 shares worth $24.9M. The position accounts for 0.02% of the portfolio, ranked #787.

Victory Capital Management first reported a position in EWTX in Q4 2024 and has held it in 5 quarters since. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • Victory Capital Management held 789,043 shares of Edgewise Therapeutics worth $24.9M as of Q1 2026.
  • Victory Capital Management bought 42,481 Edgewise Therapeutics shares in Q1 2026, an estimated $1.23M.
  • Edgewise Therapeutics made up 0.02% of Victory Capital Management's portfolio in Q1 2026, its #787 holding.
  • Victory Capital Management first reported a position in Edgewise Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on Victory Capital Management's 13F filing for Q1 2026, filed 15 May 2026.